Hormonal
GLP-1 receptor agonists (GLP1RAs) reduce the risk of total stroke by approximately 16-17% and non-fatal stroke by 15-16% in patients with type 2 diabetes, independent of their effects on weight loss.
If you have type 2 diabetes and are at high risk for heart disease or stroke, ask your doctor about GLP-1 receptor agonists. These medications not only help with blood sugar and weight but have been shown in large studies to significantly lower your risk of having a stroke. This benefit exists even if you don't lose a lot of weight.
In a meta-analysis including seven CVOTs and approximately 56 thousand participants, the use of GLP1RAs in patients with type 2 diabetes reduced the risk of total stroke by 16% (HR = 0.84; 95% CI 0.46–0.93) and the risk of non-fatal stroke by 15% (HR = 0.85; 95% CI 0.76–0.94) relative to placebo [20].
Why this rating
Based on large-scale meta-analyses of randomized clinical trials (CVOTs) involving tens of thousands of participants.
Source
Emerging Treatments for Obesity: the Role of GLP1 Receptor Agonists on Stroke
Melissa Mariscal et al. · Current Neurology and Neuroscience Reports · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →